Thymosin Alpha 1
Also known as: Ta1, Thymalfasin, Zadaxin
An immunomodulatory peptide that enhances T-cell function and immune response.
Overview
Thymosin Alpha 1 is a naturally occurring thymic peptide that plays a crucial role in immune system development and function. It has been approved in over 35 countries for treating viral hepatitis and as an immune adjuvant.
Mechanism of Action
Enhances T-cell maturation and function, stimulates dendritic cell development, increases MHC class I expression, and modulates cytokine production. Acts as an immune system regulator.
Pharmacokinetics
Rapidly absorbed after SC injection. Half-life approximately 2 hours. Peak levels within 1-2 hours.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard
1.6 mg
Twice weekly
6-12 months
Standard hepatitis protocol
Immune Support
1.6 mg
2-3x weekly
4-8 weeks
General immune enhancement
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Approved for hepatitis B and C treatment in multiple countries
- 2Enhanced vaccine response in immunocompromised patients
- 3Adjuvant benefit in cancer immunotherapy
- 4Improved outcomes in sepsis when combined with standard care
Side Effects & Contraindications
Reported Side Effects
- Injection site reactions
- Fatigue (rare)
Contraindications
- Organ transplant recipients (relative)
- Autoimmune conditions (caution)
Safety Considerations
Excellent safety profile with decades of clinical use. Rare injection site reactions.
Storage Requirements
Refrigerate at 2-8C
Scientific References
- 1